Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

Core Insights - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases [1][3] - The company presented follow-up data from its Phase 1 study of SPY003, an anti-IL-23 agent, at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO) [1][2] - SPY003 demonstrated a well-tolerated profile, a differentiated pharmacokinetic (PK) profile supporting quarterly or biannual dosing, and targeted biological activity through a reduction in downstream cytokines [2] Company Developments - The interim results from the Phase 1 study of SPY003 suggest potential maintenance dosing options of every three months (Q3M) or every six months (Q6M) for IBD [2] - Spyre is also showcasing its SKYLINE platform trial, which evaluates long-acting antibodies both as monotherapies and in rational combinations [2] - Preclinical data indicates that dual targeting of TL1A and IL-23 may provide superior efficacy compared to using either agent alone [2] Research Presentations - The presentations at ECCO include: - "Interim Phase 1 Results for SPY003, a Novel Half-Life Extended Monoclonal Antibody Targeting IL-23" [2] - "SKYLINE-UC: the First Platform Study in Ulcerative Colitis Assessing Efficacy and Safety of Three Long-acting Antibodies" [2] - "Anti-TL1A and Anti-IL-23 Combination Therapy is Superior to its Constituent Monotherapies in Mouse Anti-CD40 Colitis" [2]